Tenderwize
Wróć do wyszukiwania

Open-house rebate agreements for Natalizumab IV

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Mar 31, 2027 · 218 days left·Open·Supplies
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Natalizumab, i.v. Darreichungsform, ATC L04AG03

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply of pharmaceutical products under an open-house rebate agreement for Natalizumab, intravenous dosage form, ATC L04AG03.
  • Non-exclusive contract model with uniform terms for all participants; no individual negotiations.
Pokaż pełne podsumowanie

Open-house supply arrangement for Natalizumab (IV form, ATC L04AG03) offered by AOK Rheinland-Pfalz/Saarland. The notice states this is a non-exclusive, open-house model with uniform terms, no individual negotiations, and monthly entry possible during a maximum 24-month period. Submission is by original documents, electronic submission is not allowed, and the provided data indicates no contract value was published. The notice also states that children’s medicines listed by BfArM under §35(5a) SGB V are excluded.

Ryzyka

Submission must be in original form and electronic submission is not allowed.

Only authorised and marketable medicines in Germany may be supplied; if Lauer-Taxe evidence is missing, additional AMIc...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Only authorised and marketable medicines in Germany may be supplied under the contract.

Administrative

  • If the medicine is not listed in Lauer-Taxe at submission time, the bidder must provide an extract from the public AMIce database and, where needed, additional supporting...
  • Submission must be in original form; electronic submission is not allowed.

Zamawiający

Lokalizacja

Eisenberg, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE271900642

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreements for Natalizumab IV

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing Natalizumab in intravenous dosage form (ATC L04AG03). The buyer states that all interested pharmaceutical companies may join under identical conditions, without selection decision or individual negotiation. The lot excludes medicines listed as children’s medicines under the BfArM list referenced in the notice. Contract duration is up to 24 months, with the earliest start on 2025-06-01 and monthly entry possible; contracts end no later than 24 months after the earliest start date. The lot-level value is not provided.

SuppliesEU fundedElectronic submission

Lokalizacja

Eisenberg, Germany

Czas trwania

May 2025 - May 2027

Kategoria

Pharmaceutical products

Termin

Deadline Mar 31, 2027

Szczegóły zamówienia

Data publikacji
10 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
235853-2025

Dokumenty (1)

Podobne przetargi